Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination

Vaccine

Volumn 30, Issue 24, 2012, Pages 3572-3579

  Smolen, Kinga K ^a   Gelinas, Laura ^a   Franzen, Lisa ^b   Dobson, Simon ^a,c   Dawar, Meena ^a,d   Ogilvie, Gina ^a   Krajden, Mel ^e   Fortuno, Edgardo S ^a   Kollmann, Tobias R ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d VANCOUVER COASTAL HEALTH   (Canada)

^e BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

Author keywords

Age; Dose; ELISPOT; Human papilloma virus; Immune memory; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; B-LYMPHOCYTES; CHILD; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES; VACCINATION; YOUNG ADULT;

EID: 84861009178     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.051     Document Type: Article

References (50)

1. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370(September 8 (9590)):890-907.
2. Dauner J.G., Pan Y., Hildesheim A., Harro C., Pinto L.A. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010, 28(July 26 (33)):5407-5413.
3. Rambout L., Hopkins L., Hutton B., Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007, 177(August (285)):469-479.
4. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347(November 21 (21)):1645-1651.
5. Ault K.A. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007, 107(November (2 Suppl 1)):S27-S30.
6. Munoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373(June 6 (9679)):1949-1957.
7. Romanowski B., de Borba P.C., Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009, 374(December 12 (9706)):1975-1985.
8. Dillner J., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
9. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89(December 15 (24)):12180-12184.
10. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001, 93(February 21 (4)):284-292.
11. Schwarz T.F., Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008, 110(September (3 Suppl 1)):S1-S10.
12. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995, 92(December 5 (25)):11553-11557.
13. Einstein M.H., Schiller J.T., Viscidi R.P., Strickler H.D., Coursaget P., Tan T., et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009, 9(June (6)):347-356.
14. Frazer I. Correlating immunity with protection for HPV infection. Int J Infect Dis 2007, 11(November 1 (Suppl 2)):S10-S16.
15. Stanley M. Immune responses to human papillomavirus. Vaccine 2006, 24(March 30 (Suppl 1)):S16-S22.
16. Mariani L., Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med 2010, 8:105.
17. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24(July 7 (27-28)):5571-5583.
18. Neuzil K.M., Canh do G., Thiem V.D., Janmohamed A., Huong V.M., Tang Y., et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011, 305(April 13 (14)):1424-1431.
19. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369(June 30 (9580)):2161-2170.
20. Paavonen J., Naud P., Salmerón J., Wheeler C., Chow S., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, (July 6).
21. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, (September 9).
22. Block S.L., Nolan T., Sattler C., Barr E., Giacoletti K.E., Marchant C.D., et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006, 118(November (5)):2135-2145.
23. Pedersen C., Petaja T., Strauss G., Rumke H., Poder A., Richardus J., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007, 40(June 1 (6)):564-571.
24. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007, 26(March (3)):201-209.
25. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17(7):1055-1065.
26. Blimkie D., Fortuno E.S., Thommai F., Xu L., Fernandes E., Crabtree J., et al. Identification of B cells through negative gating - an example of the MIFlowCyt standard applied. Cytometry A 2010, 77(Jun (6)):546-551.
27. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix() and Gardasil((R)) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Human Vaccines 2009, 5(October 1 (10)):705-719.
28. Crotty S., Aubert R.D., Glidewell J., Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004, 286(March 1 (1-2)):111-122.
29. van der Burg S.H., Ressing M.E., Kwappenberg K.M., de Jong A., Straathof K., de Jong J., et al. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 2001, 91(March 1 (5)):612-618.
30. Kasturi S.P., Skountzou I., Albrecht R.A., Koutsonanos D., Hua T., Nakaya H.I., et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011, 470(February 24 (7335)):543-547.
31. Zinkernagel R.M., Bachmann M.F., Kundig T.M., Oehen S., Pirchet H., Hengartner H. On immunological memory. Annu Rev Immunol 1996, 14:333-367.
32. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003, 188(July (152)):327-338.
33. Pinto L.A., Castle P.E., Roden R.B., Harro C.D., Lowy D.R., Schiller J.T., et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 2005, 23(May 20 (27)):3555-3564.
34. Pinto L.A., Viscidi R., Harro C.D., Kemp T.J., Garcia-Pineres A.J., Trivett M., et al. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 2006, 353(September 30 (2)):451-462.
35. D'Argenio D.A., Wilson C.B. A decade of vaccines: integrating immunology and vaccinology for rational vaccine design. Immunity 2010, 33(October 29 (4)):437-440.
36. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298(December 13 (5601)):2199-2202.
37. Frazer I.H. Measuring serum antibody to human papillomavirus following infection or vaccination. Gynecol Oncol 2010, 118(June (1 Suppl)):S8-S11.
38. Blanchard-Rohner G., Pulickal A.S., Jol-van der Zijde C.M., Snape M.D., Pollard A.J. Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood 2009, 114(December 3 (24)):4998-5002.
39. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(August 14 (33-34)):5937-5949.
40. Siegrist C.A., Aspinall R. B-cell responses to vaccination at the extremes of age. Nature Rev 2009, 9(March (3)):185-194.
41. Villa L.L., Costa R.L.R., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The lancet oncology 2005, 6(May 1 (5)):271-278.
42. Scott M., Nakagawa M., Moscicki A.B. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001, 8(March (2)):209-220.
43. Coleman N., Birley H.D., Renton A.M., Hanna N.F., Ryait B.K., Byrne M., et al. Immunological events in regressing genital warts. Am J Clin Pathol 1994, 102(December (6)):768-774.
44. Nicholls P.K., Moore P.F., Anderson D.M., Moore R.A., Parry N.R., Gough G.W., et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001, 283(April 25 (1)):31-39.
45. Ohlschlager P., Osen W., Dell K., Faath S., Garcea R.L., Jochmus I., et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003, 77(April (8)):4635-4645.
46. Yao Q., Zhang R., Guo L., Li M., Chen C. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine. J Immunol 2004, 173(August 1 (3)):1951-1958.
47. Galli G., Medini D., Borgogni E., Zedda L., Bardelli M., Malzone C., et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009, 106(March 10 (10)):3877-3882.
48. Ravkov E.V., Williams M.A. The magnitude of CD4+ T cell recall responses is controlled by the duration of the secondary stimulus. J Immunol 2009, 183(August 15 (4)):2382-2389.
49. Penny M., Bartolini R., Mosqueira N.R., LaMontagne D.S., Mendoza M.A., Ramos I., et al. Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru. Vaccine 2011, 29(July 12 (31)):5022-5030.
50. Tsu V., Murray M. Limited benefit of HPV vaccination for sexually active women in developing countries. Vaccine 2011, May 14.